Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1/2 1

Status

Completed 12Terminated 9Recruiting 6Active not recruiting 5Not yet recruiting 3Withdrawn 2Unknown 1Suspended 1

Sponsor Class

OTHER 3INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Gynecologic 2Breast 2Other solid neoplasm 1Other neoplasm 1Gastrointestinal 1

Conditions

Fallopian Tube Neoplasms 2Vaccinia 1Triple Negative Breast Neoplasms 1Solid Tumors 1Ovarian Neoplasms 1HER2-negative Breast Cancer 1Gastric Adenocarcinoma 1

Interventions

pembrolizumab 555Specimen Handling 459Carboplatin 446Magnetic Resonance Spectroscopy 427Cyclophosphamide 412Cisplatin 404Gemcitabine 314Radiotherapy 313Bevacizumab 310Paclitaxel 300Biopsy 260Drug Therapy 252Capecitabine 241Oxaliplatin 240fludarabine 236Nivolumab 226venetoclax 225Injections 214Docetaxel 203Fluorouracil 201Dexamethasone 186Radiosurgery 172Rituximab 161Pemetrexed 157durvalumab 144Standard of Care 143atezolizumab 139toripalimab 137tislelizumab 137Leucovorin 137

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Interventional × taxane × Clear all
NCT05753306 2026-04-08

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Mayo Clinic

Phase 2 Recruiting
40 enrolled
GastrointestinalOther neoplasm

Gastric Adenocarcinoma

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT07158918 2025-09-08

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

ABL Bio, Inc.

Phase 1/2 Recruiting
65 enrolled
Other solid neoplasm

Solid Tumors

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting
252 enrolled
Breast

HER2-negative Breast Cancer

NCT06355037 2024-07-08

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Fudan University

Phase 2 Recruiting
10 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03983226 2022-03-18

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
167 enrolled
Gynecologic

Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡